Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia

Jack Ghannam, Laura W. Dillon, Christopher S. Hourigan

Research output: Contribution to journalReview articlepeer-review


Acute myeloid leukaemia (AML) is a blood cancer characterized by acquired genetic mutations. There is great interest in accurately establishing measurable residual disease (MRD) burden in AML patients in remission after treatment but at risk of relapse. However, inter- and intrapatient genetic diversity means that, unlike in the chronic myeloid and acute promyelocytic leukaemias, no single genetic abnormality is pathognomonic for all cases of AML MRD. Next-generation sequencing offers the opportunity to test broadly and deeply for potential genetic evidence of residual AML, and while not currently accepted for such use clinically, is likely to be increasingly used for AML MRD testing in the future.

Original languageEnglish (US)
Pages (from-to)77-85
Number of pages9
JournalBritish journal of haematology
Issue number1
StatePublished - Jan 1 2020
Externally publishedYes


  • acute myeloid leukaemia
  • genetics
  • measurable residual disease
  • minimal residual disease
  • mutation detection
  • myeloid leukaemia

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia'. Together they form a unique fingerprint.

Cite this